A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease

Manuela Contin, R. Riva, P. Martinelli, P. Cortelli, F. Albani, A. Baruzzi

Research output: Contribution to journalArticle

Abstract

Objective: The aims of the study were to follow prospectively the intrasubject progression of idiopathic PD in a cohort of patients using levodopa kinetic-dynamic modeling and to assess the relation between the rate of progression of the disease and patients' different clinical characteristics. Methods: Thirty-four patients (Hoehn and Yahr stages 1 to 3) enrolled in the longitudinal follow-up. Each patient was examined at 1-year intervals over a median 4 years by a standardized oral levodopa test. The primary measure outcome was the computed half-life of levodopa in the 'effect compartment' (t1/2(eq)), a proposed indicator of nigrostriatal dopaminergic functionality and integrity. Results: Values of levodopa t1/2(eq) correlated negatively with severity of symptoms (r = -0.652, p <0.0001) and decreased over the years together with a worsening of patients' clinical stage (p <0.001). The rate of reduction in drug t1/2(eq) was more rapid in patients at the earlier stages of the disease compared with the more advanced ones, falling from a median annual reduction of 37 minutes in patients at initial Hoehn and Yahr stage 1 to 6.5 minutes in stage 3 patients (p <0.001). Patients without tremor at onset, otherwise comparable to patients with tremor for baseline values of levodopa t1/2(eq), disease severity, duration, and daily dose of levodopa, tended to show a higher rate of reduction in levodopa t1/2(eq) than patients with tremor. Overall, patients' annual reduction in levodopa t1/2(eq) over baseline values averaged 17 ± 9%. Conclusions: These results are in keeping with PET findings on the objective assessment of idiopathic parkinsonism evolution, and they support the suggestion that levodopa pharmacodynamic modeling may offer a practical clinical tool to assess indirectly the functional integrity of the nigrostriatal dopaminergic system over time in parkinsonian patients.

Original languageEnglish
Pages (from-to)1075-1080
Number of pages6
JournalNeurology
Volume51
Issue number4
Publication statusPublished - Oct 1998

Fingerprint

Levodopa
Parkinson Disease
Tremor
Parkinsonian Disorders
Half-Life
Disease Progression
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease. / Contin, Manuela; Riva, R.; Martinelli, P.; Cortelli, P.; Albani, F.; Baruzzi, A.

In: Neurology, Vol. 51, No. 4, 10.1998, p. 1075-1080.

Research output: Contribution to journalArticle

Contin, M, Riva, R, Martinelli, P, Cortelli, P, Albani, F & Baruzzi, A 1998, 'A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease', Neurology, vol. 51, no. 4, pp. 1075-1080.
Contin, Manuela ; Riva, R. ; Martinelli, P. ; Cortelli, P. ; Albani, F. ; Baruzzi, A. / A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease. In: Neurology. 1998 ; Vol. 51, No. 4. pp. 1075-1080.
@article{f75dce7a8e56452587ee69b1cf4e1e8a,
title = "A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease",
abstract = "Objective: The aims of the study were to follow prospectively the intrasubject progression of idiopathic PD in a cohort of patients using levodopa kinetic-dynamic modeling and to assess the relation between the rate of progression of the disease and patients' different clinical characteristics. Methods: Thirty-four patients (Hoehn and Yahr stages 1 to 3) enrolled in the longitudinal follow-up. Each patient was examined at 1-year intervals over a median 4 years by a standardized oral levodopa test. The primary measure outcome was the computed half-life of levodopa in the 'effect compartment' (t1/2(eq)), a proposed indicator of nigrostriatal dopaminergic functionality and integrity. Results: Values of levodopa t1/2(eq) correlated negatively with severity of symptoms (r = -0.652, p <0.0001) and decreased over the years together with a worsening of patients' clinical stage (p <0.001). The rate of reduction in drug t1/2(eq) was more rapid in patients at the earlier stages of the disease compared with the more advanced ones, falling from a median annual reduction of 37 minutes in patients at initial Hoehn and Yahr stage 1 to 6.5 minutes in stage 3 patients (p <0.001). Patients without tremor at onset, otherwise comparable to patients with tremor for baseline values of levodopa t1/2(eq), disease severity, duration, and daily dose of levodopa, tended to show a higher rate of reduction in levodopa t1/2(eq) than patients with tremor. Overall, patients' annual reduction in levodopa t1/2(eq) over baseline values averaged 17 ± 9{\%}. Conclusions: These results are in keeping with PET findings on the objective assessment of idiopathic parkinsonism evolution, and they support the suggestion that levodopa pharmacodynamic modeling may offer a practical clinical tool to assess indirectly the functional integrity of the nigrostriatal dopaminergic system over time in parkinsonian patients.",
author = "Manuela Contin and R. Riva and P. Martinelli and P. Cortelli and F. Albani and A. Baruzzi",
year = "1998",
month = "10",
language = "English",
volume = "51",
pages = "1075--1080",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease

AU - Contin, Manuela

AU - Riva, R.

AU - Martinelli, P.

AU - Cortelli, P.

AU - Albani, F.

AU - Baruzzi, A.

PY - 1998/10

Y1 - 1998/10

N2 - Objective: The aims of the study were to follow prospectively the intrasubject progression of idiopathic PD in a cohort of patients using levodopa kinetic-dynamic modeling and to assess the relation between the rate of progression of the disease and patients' different clinical characteristics. Methods: Thirty-four patients (Hoehn and Yahr stages 1 to 3) enrolled in the longitudinal follow-up. Each patient was examined at 1-year intervals over a median 4 years by a standardized oral levodopa test. The primary measure outcome was the computed half-life of levodopa in the 'effect compartment' (t1/2(eq)), a proposed indicator of nigrostriatal dopaminergic functionality and integrity. Results: Values of levodopa t1/2(eq) correlated negatively with severity of symptoms (r = -0.652, p <0.0001) and decreased over the years together with a worsening of patients' clinical stage (p <0.001). The rate of reduction in drug t1/2(eq) was more rapid in patients at the earlier stages of the disease compared with the more advanced ones, falling from a median annual reduction of 37 minutes in patients at initial Hoehn and Yahr stage 1 to 6.5 minutes in stage 3 patients (p <0.001). Patients without tremor at onset, otherwise comparable to patients with tremor for baseline values of levodopa t1/2(eq), disease severity, duration, and daily dose of levodopa, tended to show a higher rate of reduction in levodopa t1/2(eq) than patients with tremor. Overall, patients' annual reduction in levodopa t1/2(eq) over baseline values averaged 17 ± 9%. Conclusions: These results are in keeping with PET findings on the objective assessment of idiopathic parkinsonism evolution, and they support the suggestion that levodopa pharmacodynamic modeling may offer a practical clinical tool to assess indirectly the functional integrity of the nigrostriatal dopaminergic system over time in parkinsonian patients.

AB - Objective: The aims of the study were to follow prospectively the intrasubject progression of idiopathic PD in a cohort of patients using levodopa kinetic-dynamic modeling and to assess the relation between the rate of progression of the disease and patients' different clinical characteristics. Methods: Thirty-four patients (Hoehn and Yahr stages 1 to 3) enrolled in the longitudinal follow-up. Each patient was examined at 1-year intervals over a median 4 years by a standardized oral levodopa test. The primary measure outcome was the computed half-life of levodopa in the 'effect compartment' (t1/2(eq)), a proposed indicator of nigrostriatal dopaminergic functionality and integrity. Results: Values of levodopa t1/2(eq) correlated negatively with severity of symptoms (r = -0.652, p <0.0001) and decreased over the years together with a worsening of patients' clinical stage (p <0.001). The rate of reduction in drug t1/2(eq) was more rapid in patients at the earlier stages of the disease compared with the more advanced ones, falling from a median annual reduction of 37 minutes in patients at initial Hoehn and Yahr stage 1 to 6.5 minutes in stage 3 patients (p <0.001). Patients without tremor at onset, otherwise comparable to patients with tremor for baseline values of levodopa t1/2(eq), disease severity, duration, and daily dose of levodopa, tended to show a higher rate of reduction in levodopa t1/2(eq) than patients with tremor. Overall, patients' annual reduction in levodopa t1/2(eq) over baseline values averaged 17 ± 9%. Conclusions: These results are in keeping with PET findings on the objective assessment of idiopathic parkinsonism evolution, and they support the suggestion that levodopa pharmacodynamic modeling may offer a practical clinical tool to assess indirectly the functional integrity of the nigrostriatal dopaminergic system over time in parkinsonian patients.

UR - http://www.scopus.com/inward/record.url?scp=0031661261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031661261&partnerID=8YFLogxK

M3 - Article

C2 - 9781532

AN - SCOPUS:0031661261

VL - 51

SP - 1075

EP - 1080

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -